Ultimately, the LACEWING study failed to show a significant benefit to the addition of gilteritinib to azacitidine in older patients with newly diagnosed FLT3-mutated AML and suggests that use of these doublets may not be optimal in this population. This evidence concerns the gene FLT3 and acute myeloid leukemia.